Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Lifileucel |
Synonyms | |
Therapy Description |
LN-144 (lifileucel) is a preparation of tumor infiltrating lymphocytes isolated and expanded from patient tumor tissue, which may demonstrate enhanced anti-tumor immune activity when re-introduced into patients (Journal of Clinical Oncology 35, no. 15_suppl (May 20 2017) 3045-3045). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Lifileucel | Amtagvi | LN-144|LN144|LN 144 | Amtagvi (lifileucel) is a preparation of tumor-infiltrating lymphocytes isolated and expanded from patient tumor tissue, which may demonstrate enhanced anti-tumor immune activity when re-introduced into patients (PMID: 33979178). Amtagvi (lifileucel) is FDA-approved for use in patients with previously treated unresectable or metastatic melanoma (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06566092 | Phase I | Lifileucel LN-145 | Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants | Recruiting | USA | 0 |
NCT05640193 | Phase I | Lifileucel | Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients With Asymptomatic Melanoma Brain Metastases | Active, not recruiting | USA | 0 |
NCT05607095 | Phase I | Lifileucel | Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients With Metastatic Uveal Melanoma | Recruiting | USA | 0 |
NCT06190249 | Phase I | Cyclophosphamide + Fludarabine Lifileucel Pembrolizumab Aldesleukin Mesna | Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma | Suspended | USA | 0 |
NCT02360579 | Phase II | Lifileucel | Study of LN-144, Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma (LN-144) | Active, not recruiting | USA | ITA | HUN | GBR | FRA | ESP | DEU | CHE | 0 |
NCT05398640 | Expanded access | Lifileucel | Expanded Access Program of Lifileucel (LN-144) in Patients With Unresectable or Metastatic Melanoma | Available | USA | 0 |
NCT06151847 | Phase II | Cyclophosphamide + Fludarabine Lifileucel Aldesleukin | Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma | Recruiting | USA | 0 |